Sec­tion 3. Pre­ven­tion or De­lay of Type 2 Di­a­betes and As­so­ci­at­ed Co­mor­bidi­ties

(https:/​/​doi.org/​10.2337/​dc23-​S003)

Rec­om­men­da­tion 3.9 was added to ad­dress statin use and the risk of type 2 di­a­betes, in­clud­ing the rec­om­men­da­tion to mon­i­tor glu­cose sta­tus reg­u­lar­ly and en­force di­a­betes pre­ven­tion ap­proach­es in in­di­vid­u­als at high risk of de­vel­op­ing type 2 di­a­betes who were pre­scribed statin ther­a­py.

Rec­om­men­da­tion 3.10 was added to ad­dress the use of pi­ogli­ta­zone for re­duc­ing the risk of stroke or my­ocar­dial in­farc­tion in peo­ple with his­to­ry of stroke and ev­i­dence of in­sulin re­sis­tance and pre­di­a­betes.

Rec­om­men­da­tion 3.12 was added to com­mu­ni­cate that phar­ma­cother­a­py (e.g., weight man­age­ment, min­i­miz­ing the pro­gres­sion of hy­per­glycemia, car­dio­vas­cu­lar risk re­duc­tion) may be con­sid­ered to sup­port per­son-​cen­tered care goals for peo­ple at high risk of de­vel­op­ing di­a­betes.

Rec­om­men­da­tion 3.13 was added to state that more in­ten­sive pre­ven­tive ap­proach­es should be con­sid­ered for in­di­vid­u­als who are at par­tic­u­lar­ly high risk of pro­gres­sion to di­a­betes.